EP3458441B1 - Process for the manufacture of 6-alkynyl-pyridine derivatives - Google Patents

Process for the manufacture of 6-alkynyl-pyridine derivatives Download PDF

Info

Publication number
EP3458441B1
EP3458441B1 EP17726859.6A EP17726859A EP3458441B1 EP 3458441 B1 EP3458441 B1 EP 3458441B1 EP 17726859 A EP17726859 A EP 17726859A EP 3458441 B1 EP3458441 B1 EP 3458441B1
Authority
EP
European Patent Office
Prior art keywords
alkyl
formula
compound
hydrogen
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP17726859.6A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3458441A1 (en
Inventor
Guanghua LU
Guenther Huchler
Thomas Krueger
Michael PANGERL
Marco Santagostino
Jean-Nicolas DESROSIERS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of EP3458441A1 publication Critical patent/EP3458441A1/en
Application granted granted Critical
Publication of EP3458441B1 publication Critical patent/EP3458441B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Definitions

  • the present invention relates to a process for the manufacture of 6-alkynyl-pyridine imidazopyridine derivatives and a pharmaceutically acceptable salt thereof More specifically, the process of the invention relates to a process for the synthesis of compounds of Formula I, II or III, wherein the groups R 1 to R 3 , R a and R b are defined herein below, and to new intermediates of this process.
  • the application includes a description of novel intermediates, of new manufacturing steps resulting in a novel and improved process for producing the intermediates and the final compounds, i . e ., 6-alkynyl-pyridine derivatives.
  • the intermediates of the invention are useful to produce 6-alkynyl-pyridine derivatives, which compounds are useful for the treatment of cancer.
  • the process of the invention relates to the synthesis of the compounds of formula wherein
  • the process of the invention relates to the synthesis of compounds of formula wherein
  • the process of the invention relates to the synthesis of compounds of formula wherein
  • 6-Alkynyl-pyridine derivatives and their salts are known from the following patent and patent applications: US 8,859,541 , WO 2013/127729 , WO 2016/023858 . These patent applications disclose the compounds, a process for their manufacture and the use of the compounds or their salts in a pharmaceutical composition to treat oncological or non-oncological diseases via inhibition of the proliferation of target cells, alone or in combination with further therapeutic agents.
  • the mechanism of action by which the proliferation of the target cells occurs is essentially a protein-protein interaction, and especially a IAP-SMAC inhibition.
  • the method of the prior art comprises a Sonogashira cross coupling reaction at the C-6 position of a pyridine ring between 5,6-dibromo-pyridin-2-yl-amine and a trialkylsilyl acetylene to give a Si(alkyl) 3 protected 6-alkynyl-pyridine.
  • This is in turn acylated at the NH 2 moiety on C-2 using a 2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]propanoic acid.
  • an imidazo[1,2- a ]pyridine substituent (R x or R y Br) is installed at the C-5 position of the pyridine ring by a two-step sequence comprising a Miyaura borylation followed by a Suzuki cross coupling.
  • R x or R y Br an imidazo[1,2- a ]pyridine substituent
  • the synthetic route continues by removing the silicon protecting group on the alkyne moiety, which eventually allows to implement a second Sonogashira cross coupling to install the R 3 group before removing the N -Boc protecting group in order to complete the synthesis.
  • the process described in the prior art has the following disadvantages: First of all, boronic acid derivatives are used. Furthermore, five of the intermediates bear the expensive trialkylsilyl group, and these intermediates can be purified only via chromatography.
  • a first advantage of the process of the invention is that it is more convergent.
  • the process of the prior art is based on a (seven) eight-step linear synthesis whereas the new synthesis is more convergent resulting in only six linear steps, thus improving the overall synthetic efficiency and throughput.
  • a second advantage is that the improved process avoids the use of boronic acids intermediates (or their esters) and of the diboron compounds used for their preparation via Miyaura borylation. As also stated above, this class of compounds is known to pose a health risk associated with their handling. ( Org. Process Res. Dev. 2015, 19, 1507-1516 ). This can be avoided using the process of the invention.
  • a third advantage is that the improved process makes use of a N , N -dimethylformamidine protecting group ( J. Org. Chem., 2008, 73 (22), 8954-8959 ) to mask the -NH 2 functionality on the pyridine core.
  • This protecting group is very easy to install, surprisingly stable under the used reaction conditions and is easy to remove under a variety of conditions compatible with the presence of an alkyne moiety.
  • the N , N- dimethylformamidine protecting group allows cross coupling reactions using basic organometallic reagents, such as organozinc compounds and proved to be essential for direct arylation procedure using imidazo[1,2- a ]pyridines as nucleophiles.
  • a fourth advantage is that in the process of the invention the polyaromatic core is prepared upstream in the synthetic sequence using conditions which are amenable for the large scale production and are more friendly towards the environment than the processes already known from the prior art.
  • the steps leading to pivotal intermediates III are conducted at high concentrations. This implies a reduction of volume-time output (VTO) which correlates inversely with the cost of plant occupancy and reduced solvent and waste costs.
  • VTO volume-time output
  • (poly)aromatic intermediates lacking the 2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]propanoyl and the lipophilic tri(propan-2-yl)silyl moieties like the intermediates A-M exemplified in the improved process are in general highly crystalline compounds and their purification can be mainly conducted via crystallization with obvious benefits over the column chromatography purification method which is necessary according to above-mentioned patent applications.
  • a fifth advantage of the improved process is an extremely limited use of the labile trialkylsilyl protecting groups.
  • a trimethylsilyl group is used as temporary protecting group only for the preparation of the intermediate E1.
  • the trialkylsilyl protecting group is introduced at the very beginning and is maintained for most of the synthetic sequence.
  • the use of expensive ethynyl-tri(propan-2-yl)silane is necessary to avoid undesired deprotection along the synthetic sequence.
  • a sixth advantage is that while in the above-mentioned patent applications the expensive and sensitive 2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino] propanoyl moiety is introduced at the very beginning of the synthetic sequence, in the improved process this is installed at the very end of the synthesis.
  • the present inventors have accomplished the present invention by developing a novel method for the large scale preparation in high yield of 6-alkynyl-pyridine compounds and intermediates en route to their synthesis.
  • the invention relates to a process for the synthesis of compounds of formula wherein
  • the invention relates to a process for the synthesis of a compound of formula comprising the steps of
  • the invention relates to a process for the synthesis of a compound of formula wherein
  • a compound of formula is obtained by deprotection of a compound of formula wherein A is absent or is a 6-membered nitrogen containing heteroaryl optionally substituted with a -C 1-3 alkyl group.
  • R x denotes H or -CH 3 .
  • the trialkylsilylacetylene is trimethylsilylacetylene.
  • the process for obtaining compounds of formula II or I comprises the steps of
  • the process of the invention relates to compounds wherein R z is selected from -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 and R a and R b are the same or different selected from -CH 3 , -CH 2 CH 3 , -CH(CH) 2 , -C(CH 3 ) 3 , or -CH 2 -phenyl or R a and R b together form pyrrolidine, piperidine or hexahydro-1 H -azepine.
  • R a and R b are both -CH 3 .
  • the compounds of formula III can be further reacted with intermediates of formula J or K to obtain compounds of formula II.
  • the compounds of formula III can be further reacted to obtain compounds of formula II and which can be further reacted to obtain compounds of formula I.
  • the process for obtaining compounds of formula II or III further comprises the step of
  • the process for obtaining compounds of formula II or III further comprises the step of coupling a compound of formula M with 2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]propanoic acid, wherein the 2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]propanoic acid is racemic, S -2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]propanoic acid or R -2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]propanoic acid, to form a compound of formula
  • the process for obtaining compounds of formula II or III further comprises the step of deprotecting the compounds of formula N to give a compound of formula I.
  • A is absent or is a 6-membered nitrogen containing heteroaryl, with one or two nitrogen atoms, preferably one, and optionally substituted with -CH 3 .
  • R 3 is selected from -C 1-3 alkyl, preferably -CH 3 and a 6-membered nitrogen containing heteroaryl, preferably pyridyl, which pyridyl is optionally substituted with -CH 3 or -O-CH 3 , preferably -O-CH 3 .
  • R 2 is selected from hydrogen or methyl.
  • R 1 is selected from hydrogen or methyl.
  • -C 1-5 alkyl means an alkyl group or radical having 1 to 5 carbon atoms.
  • the first named sub-group is the radical attachment point, for example the substitutent -C 1-5 alkyl-C 3-10 cylcoalkyl, means a C 3-10 cycloalkyl group which is bound to a C 1-5 alkyl, the latter of which is bound to the core structure or to the group to which the substitutent is attached.
  • the indication of the number of members in groups that contain one or more heteroatom(s) (heteroalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocycylalkyl) relates to the total atomic number of all the ring members or chain members or the total of all the ring and chain members.
  • substituent groups containing a nitrogen atom can also be indicated as amine or amino.
  • groups containing oxygen atom can also be indicated with -oxy, like for example alkoxy.
  • Groups containing -C(O)- can also be indicated as carboxy; groups containing -NC(O)- can also be indicated as amide; groups containing -NC(O)N- can also be indicated as urea; groups containing -NS(O) 2 - can also be indicated as sulfonamide.
  • Alkyl denotes monovalent, saturated hydrocarbon chains, which may be present in both linear and branched form. If an alkyl is substituted, the substitution may take place independently of one another, by mono- or polysubstitution in each case, on all the hydrogen-carrying carbon atoms.
  • C 1-5 -alkyl includes for example methyl (Me; -CH 3 ), ethyl (Et; -CH 2 CH 3 ), 1-propyl ( n -propyl; n -Pr; -CH 2 CH 2 CH 3 ), 2-propyl ( i -Pr; iso -propyl; -CH(CH 3 ) 2 ), 1-butyl ( n -butyl; n -Bu; -CH 2 CH 2 CH 2 CH 3 ), 2-methyl-1-propyl ( iso -butyl; i -Bu; -CH 2 CH(CH 3 ) 2 ), 2-butyl ( sec -butyl; sec -Bu; -CH(CH 3 )CH 2 CH 3 ), 2-methyl-2-propyl ( tert -butyl; t -Bu; -C(CH 3 ) 3 ), 1-pentyl ( n -pentyl; -CH 2
  • propyl, butyl, pentyl, etc. without any further definition are meant saturated hydrocarbon groups with the corresponding number of carbon atoms, wherein all isomeric forms are included.
  • alkyl also applies if alkyl is a part of another group such as for example C x-y -alkyl amino or C x-y -alkyl oxy or C x-y -alk oxy, wherein C x-y -alkyl oxy and C x-y -alk oxy indicate the same group.
  • alkylene can also be derived from alkyl.
  • Alkylene is bivalent, unlike alkyl, and requires two binding partners. Formally, the second valency is produced by removing a hydrogen atom in an alkyl.
  • Corresponding groups are for example -CH 3 and -CH 2 , -CH 2 CH 3 and -CH 2 CH 2 or >CHCH 3 etc.
  • C 1-4 -alkylene includes for example -(CH 2 )-, -(CH 2 -CH 2 )-, -(CH(CH 3 )) - , -(CH 2 -CH 2 -CH 2 ) - , -(C(CH 3 ) 2 ) - , -(CH(CH 2 CH 3 )) - , -(CH(CH 3 )-CH 2 )-, -(CH(CH 3 )-CH 2 )-, -(CH 2 -CH(CH 3 )) - , -(CH 2 -CH 2 -CH 2 -CH 2 ) - , -(CH 2 -CH 2 -CH(CH 3 )) - , -(CH(CH 3 )-CH 2 -CH 2 )-, -(CH 2 -CH(CH 3 )-CH 2 -CH 2 )-, -(CH 2 -CH(CH 3 )-CH 2
  • alkylene examples include methylene, ethylene, propylene, 1-methylethylene, butylene, 1-methylpropylene, 1.1-dimethylethylene, 1,2-dimethylethylene, pentylene, 1,1-dimethylpropylene, 2,2-dimethylpropylene, 1,2-dimethylpropylene, 1,3-dimethylpropylene, etc.
  • propylene includes 1-methylethylene and butylene includes 1-methylpropylene, 2-methylpropylene, 1,1-dimethylethylene and 1,2-dimethylethylene.
  • alkylene also applies if alkylene is part of another group such as for example in HO-C x-y -alkylen amino or H 2 N-C x-y -alkylen oxy.
  • alkenyl consists of at least two carbon atoms, wherein at least two adjacent carbon atoms are joined together by a C-C double bond. If in an alkyl as hereinbefore defined having at least two carbon atoms, two hydrogen atoms on adjacent carbon atoms are formally removed and the free valencies are saturated to form a second bond, the corresponding alkenyl is formed.
  • alkenyl examples include vinyl (ethenyl), prop-1-enyl, allyl (prop-2-enyl), isopropenyl, but-1-enyl, but-2-enyl, but-3-enyl, 2-methyl-prop-2-enyl, 2-methyl-prop-1-enyl, 1-methyl-prop-2-enyl, 1-methyl-prop-1-enyl, 1-methylidenepropyl, pent-1-enyl, pent-2-enyl, pent-3-enyl, pent-4-enyl, 3-methyl-but-3-enyl, 3-methyl-but-2-enyl, 3-methyl-but-1-enyl, hex-1-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl, hex-5-enyl, 2,3-dimethyl-but-3-enyl, 2,3-dimethyl-but-2-enyl, 2-methylidene-3-methylbuty
  • propenyl includes prop-1-enyl and prop-2-enyl
  • butenyl includes but-1-enyl, but-2-enyl, but-3-enyl, 1-methyl-prop-1-enyl, 1-methyl-prop-2-enyl etc.
  • Alkenyl may optionally be present in the cis or trans or E or Z orientation with regard to the double bond(s).
  • alkenyl also applies when alkenyl is part of another group such as for example in C x-y -alkenyl amino or C x-y -alkenyl oxy.
  • alkenylene consists of at least two carbon atoms, wherein at least two adjacent carbon atoms are joined together by a C-C double bond. If in an alkylene as hereinbefore defined having at least two carbon atoms, two hydrogen atoms at adjacent carbon atoms are formally removed and the free valencies are saturated to form a second bond, the corresponding alkenylene is formed.
  • alkenylene examples include ethenylene, propenylene, 1-methylethenylene, butenylene, 1-methylpropenylene, 1,1-dimethylethenylene, 1,2-dimethylethenylene, pentenylene, 1,1-dimethylpropenylene, 2,2-dimethylpropenylene, 1,2-dimethylpropenylene, 1,3-dimethylpropenylene, hexenylene etc.
  • propenylene includes 1-methylethenylene and butenylene includes 1-methylpropenylene, 2-methylpropenylene, 1,1-dimethylethenylene and 1,2-dimethylethenylene.
  • Alkenylene may optionally be present in the cis or trans or E or Z orientation with regard to the double bond(s).
  • alkenylene also applies when alkenylene is a part of another group as in for example HO-C x-y -alkenylen amino or H 2 N-C x-y -alkenylen oxy.
  • alkynyl consists of at least two carbon atoms, wherein at least two adjacent carbon atoms are joined together by a C-C triple bond. If in an alkyl as hereinbefore defined having at least two carbon atoms, two hydrogen atoms in each case at adjacent carbon atoms are formally removed and the free valencies are saturated to form two further bonds, the corresponding alkynyl is formed.
  • alkynyl examples include ethynyl, prop-1-ynyl, prop-2-ynyl, but-1-ynyl, but-2-ynyl, but-3-ynyl, 1-methyl-prop-2-ynyl, pent-1-ynyl, pent-2-ynyl, pent-3-ynyl, pent-4-ynyl, 3-methyl-but-1-ynyl.
  • propynyl includes prop-1-ynyl and prop-2-ynyl
  • butynyl includes but-1-ynyl, but-2-ynyl, but-3-ynyl, 1-methyl-prop-1-ynyl, 1-methyl-prop-2-ynyl.
  • hydrocarbon chain carries both at least one double bond and also at least one triple bond, by definition it belongs to the alkynyl subgroup.
  • alkynyl also applies if alkynyl is part of another group, as in C x-y -alkynyl amino or C x-y -alkynyl oxy, for example.
  • alkynylene consists of at least two carbon atoms, wherein at least two adjacent carbon atoms are joined together by a C-C triple bond. If in an alkylene as hereinbefore defined having at least two carbon atoms, two hydrogen atoms in each case at adjacent carbon atoms are formally removed and the free valencies are saturated to form two further bonds, the corresponding alkynylene is formed.
  • alkynylene examples include ethynylene, propynylene, 1-methylethynylene, butynylene, 1-methylpropynylene, 1,1-dimethylethynylene, 1,2-dimethylethynylene, pentynylene, 1,1-dimethylpropynylene, 2,2-dimethylpropynylene, 1,2-dimethylpropynylene, 1,3-dimethylpropynylene, hexynylene etc.
  • propynylene includes 1-methylethynylene and butynylene includes 1-methylpropynylene, 2-methylpropynylene, 1,1-dimethylethynylene and 1,2-dimethylethynylene.
  • alkynylene also applies if alkynylene is part of another group, as in HO-C x-y -alkynylene amino or H 2 N-C x-y -alkynylene oxy, for example.
  • heteroatoms oxygen, nitrogen and sulphur atoms.
  • Haloalkyl (haloalkenyl, haloalkynyl) is derived from the previously defined alkyl (alkenyl, alkynyl) by replacing one or more hydrogen atoms of the hydrocarbon chain independently of one another by halogen atoms, which may be identical or different. If a haloalkyl (haloalkenyl, haloalkynyl) is to be further substituted, the substitutions may take place independently of one another, in the form of mono- or polysubstitutions in each case, on all the hydrogen-carrying carbon atoms.
  • haloalkyl haloalkenyl, haloalkynyl
  • haloalkyl haloalkenyl, haloalkynyl
  • -CCl CH 2
  • -CBr CH 2
  • -CI CH 2 , -C ⁇ C-CF 3 , -CHFCH 2 CH 3 , -CHFCH 2 CF 3 etc.
  • haloalkyl haloalkenyl, haloalkynyl
  • haloalkylene haloalkenylene, haloalkynylene
  • Haloalkylene haloalkenyl, haloalkynyl
  • the second valency is formed by removing a hydrogen atom from a haloalkyl.
  • Corresponding groups are for example -CH 2 F and -CHF-, -CHFCH 2 F and -CHFCHF- or >CFCH 2 F etc.
  • Halogen relates to fluorine, chlorine, bromine and/or iodine atoms.
  • Cycloalkyl is made up of the subgroups monocyclic hydrocarbon rings, bicyclic hydrocarbon rings and spiro-hydrocarbon rings. The systems are saturated. In bicyclic hydrocarbon rings two rings are joined together so that they have at least two carbon atoms together. In spiro-hydrocarbon rings a carbon atom (spiroatom) belongs to two rings together. If a cycloalkyl is to be substituted, the substitutions may take place independently of one another, in the form of mono- or polysubstitutions in each case, on all the hydrogen-carrying carbon atoms. Cycloalkyl itself may be linked as a substituent to the molecule via every suitable position of the ring system.
  • cycloalkyl examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[2.2.0]hexyl, bicyclo[3.2.0]heptyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[4.3.0]nonyl (octahydroindenyl), bicyclo[4.4.0]decyl (decahydronaphthalene), bicyclo[2.2.1]heptyl (norbornyl), bicyclo[4.1.0]heptyl (norcaranyl), bicyclo-[3.1.1]heptyl (pinanyl), spiro[2.5]octyl, spiro[3.3]heptyl etc.
  • cycloalkyl also applies if cycloalkyl is part of another group as in C x-y -cycloalkyl amino or C x-y -cycloalkyl oxy, for example.
  • cycloalkylene can thus be derived from the previously defined cycloalkyl.
  • Cycloalkylene unlike cycloalkyl, is bivalent and requires two binding partners.
  • the second valency is obtained by removing a hydrogen atom from a cycloalkyl.
  • Corresponding groups are for example cyclohexyl and (cyclohexylene).
  • the above definition for cycloalkylene also applies if cycloalkylene is part of another group as in HO-C x-y -cycloalkylene amino or H 2 N-C x-y -cycloalkylene oxy, for example.
  • Cycloalkenyl is also made up of the subgroups monocyclic hydrocarbon rings, bicyclic hydrocarbon rings and spiro-hydrocarbon rings. However, the systems are unsaturated, i.e. there is at least one C-C double bond but no aromatic system. If in a cycloalkyl as hereinbefore defined two hydrogen atoms at adjacent cyclic carbon atoms are formally removed and the free valencies are saturated to form a second bond, the corresponding cycloalkenyl is obtained. If a cycloalkenyl is to be substituted, the substitutions may take place independently of one another, in the form of mono- or polysubstitutions in each case, on all the hydrogen-carrying carbon atoms. Cycloalkenyl itself may be linked as a substituent to the molecule via every suitable position of the ring system.
  • cycloalkenyl examples include cycloprop-1-enyl, cycloprop-2-enyl, cyclobut-1-enyl, cyclobut-2-enyl, cyclopent-1-enyl, cyclopent-2-enyl, cyclopent-3-enyl, cyclohex-1-enyl, cyclohex-2-enyl, cyclohex-3-enyl, cyclohept-1-enyl, cyclohept-2-enyl, cyclohept-3-enyl, cyclohept-4-enyl, cyclobuta-1,3-dienyl, cyclopenta-1,4-dienyl, cyclopenta-1,3-dienyl, cyclopenta-2,4-dienyl, cyclohexa-1,3-dienyl, cyclohexa-1,5-dienyl, cyclohexa-2,4-dien
  • cycloalkenylene can thus be derived from the previously defined cycloalkenyl.
  • Cycloalkenylene unlike cycloalkenyl, is bivalent and requires two binding partners. Formally the second valency is obtained by removing a hydrogen atom from a cycloalkenyl.
  • Corresponding groups are for example cyclopentenyl and (cyclopentenylene) etc.
  • cycloalkenylene also applies when cycloalkenylene is part of another group as in HO-C x-y -cycloalkenylene amino or H 2 N-C x-y -cycloalkenylene oxy, for example.
  • Aryl denotes a mono-, bi- or tricyclic group with at least one aromatic carbocycle. Preferably it denotes a a monocyclic group with six carbon atoms (phenyl) or a bicyclic group with nine or ten carbon atoms (two six-membered rings or one six-membered ring with a five-membered ring), wherein the second ring may also be aromatic or, however, may also be saturated or partially saturated. If an aryl is to be substituted, the substitutions may take place independently of one another, in the form of mono- or polysubstitutions in each case, on all the hydrogen-carrying carbon atoms.
  • Aryl itself may be linked as a substituent to the molecule via every suitable position of the ring system.
  • aryl examples include phenyl, naphthyl, indanyl (2,3-dihydroindenyl), indenyl, anthracenyl, phenanthrenyl, tetrahydronaphthyl (1,2,3,4-tetrahydronaphthyl, tetralinyl), dihydronaphthyl (1,2- dihydronaphthyl), fluorenyl etc.
  • aryl also applies when aryl is part of another group as in aryl amino or aryl oxy, for example.
  • arylene can also be derived from the previously defined aryl.
  • Arylene unlike aryl, is bivalent and requires two binding partners. Formally, the second valency is formed by removing a hydrogen atom from an aryl.
  • Corresponding groups are e.g. phenyl and ( o, m , p -phenylene), naphthyl and
  • arylene also applies when arylene is part of another group as in HO- arylene amino or H 2 N -arylene oxy for example.
  • heterocyclyl is made up of the subgroups monocyclic heterorings, bicyclic heterorings, tricyclic heterorings and spiro-heterorings, which may be present in saturated or unsaturated form.
  • Saturated and unsaturated, non aromatic, heterocyclyl are also defined as heterocycloalkyl.
  • unsaturated is meant that there is at least one double bond in the ring system in question, but no heteroaromatic system is formed.
  • bicyclic heterorings two rings are linked together so that they have at least two (hetero)atoms in common.
  • a carbon atom belongs to two rings together. If a heterocyclyl is substituted, the substitutions may take place independently of one another, in the form of mono- or polysubstitutions in each case, on all the hydrogen-carrying carbon and/or nitrogen atoms. Heterocyclyl itself may be linked as a substituent to the molecule via every suitable position of the ring system. When the heterocyclyl has a nitrogen atom, the preferred position to bind the heterocyclyl substituent to the molecule is the nitrogen atom.
  • heterocyclyl examples include tetrahydrofuryl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, thiazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidinyl, piperazinyl, oxiranyl, aziridinyl, azetidinyl, 1,4-dioxanyl, azepanyl, diazepanyl, morpholinyl, thiomorpholinyl, homomorpholinyl, homopiperidinyl, homopiperazinyl, homothiomorpholinyl, thiomorpholinyl- S -oxide, thiomorpholinyl- S , S -dioxide, 1,3-dioxolanyl, tetrahydropyranyl, tetrahydrothiopyranyl, [1.4]-oxazepanyl, tetrahydro
  • heterocyclyl also applies if heterocyclyl is part of another group as in heterocyclyl amino or heterocyclyl oxy for example.
  • heterocyclylene is also derived from the previously defined heterocyclyl.
  • Heterocyclylene unlike heterocyclyl, is bivalent and requires two binding partners. Formally, the second valency is obtained by removing a hydrogen atom from a heterocyclyl.
  • Corresponding groups are for example piperidinyl and 2,3-dihydro-1 H -pyrrolyl and etc.
  • heterocyclylene also applies if heterocyclylene is part of another group as in HO- heterocyclylene amino or H 2 N -heterocyclylene oxy for example.
  • Heteroaryl denotes monocyclic heteroaromatic rings or polycyclic rings with at least one heteroaromatic ring, which compared with the corresponding aryl or cycloalkyl (cycloalkenyl) contain, instead of one or more carbon atoms, one or more identical or different heteroatoms, selected independently of one another from among nitrogen, sulphur and oxygen, wherein the resulting group must be chemically stable.
  • the prerequisite for the presence of heteroaryl is a heteroatom and a heteroaromatic system. If a heteroaryl is to be substituted, the substitutions may take place independently of one another, in the form of mono- or polysubstitutions in each case, on all the hydrogen-carrying carbon and/or nitrogen atoms.
  • Heteroaryl itself may be linked as a substituent to the molecule via every suitable position of the ring system, both carbon and nitrogen.
  • heteroaryl are furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, pyridyl- N -oxide, pyrrolyl- N -oxide, pyrimidinyl- N -oxide, pyridazinyl- N -oxide, pyrazinyl- N -oxide, imidazolyl- N -oxide, isoxazolyl- N -oxide, oxazolyl
  • heteroaryl also applies when heteroaryl is part of another group as in heteroarylamino or heteroaryloxy, for example.
  • heteroarylene can therefore be derived from the previously defined heteroaryl.
  • Heteroarylene unlike heteroaryl, is bivalent and requires two binding partners. Formally, the second valency is obtained by removing a hydrogen atom from a heteroaryl.
  • Corresponding groups are for example pyrrolyl and etc.
  • heteroarylene also applies when heteroarylene is part of another group as in HO- heteroarylene amino or H 2 N -heteroarylene oxy, for example.
  • the bivalent groups mentioned above (alkylene, alkenylene, alkynylene etc.) may also be part of composite groups (e.g. H 2 N-C 1-4 alkylene- or HO-C 1-4 alkylene-). In this case one of the valencies is saturated by the attached group (here: -NH 2 , -OH), so that a composite group of this kind written in this way is only a monovalent substituent over all.
  • substituted By substituted is meant that a hydrogen atom which is bound directly to the atom under consideration, is replaced by another atom or another group of atoms (substituent). Depending on the starting conditions (number of hydrogen atoms) mono- or polysubstitution may take place on one atom. Substitution with a particular substituent is only possible if the permitted valencies of the substituent and of the atom that is to be substituted correspond to one another and the substitution leads to a stable compound ( i.e. to a compound which is not converted spontaneously, e.g. by rearrangement, cyclisation or elimination).
  • substitution may be carried out by a bivalent substituent only at ring systems and requires replacement by two geminal hydrogen atoms, i . e . hydrogen atoms that are bound to the same carbon atom that is saturated prior to the substitution. Substitution by a bivalent substituent is therefore only possible at the group -CH 2 - or sulphur atoms of a ring system.
  • the process of the invention comprises the steps of reacting an alkyne of the type E via a Sonogashira cross coupling.
  • the reaction of alkynes of the type E with the amidine B is carried out in the presence of a palladium source, a copper(I) salt, a base and optionally of ( L )-ascorbic acid and of a ligand.
  • the palladium source is a stable palladium complex such as bis(triphenylphosphinepalladium)dichloride.
  • Preferred ligand is a phosphine ligand such as triphenylphosphine.
  • copper(I) salt is preferably used copper iodide and the preferred base is an amine such as diisopropylamine, diisopropylethylamine or triethylamine.
  • the reaction can be carried out in alcohols, acetonitrile, ethers or toluene, preferably in toluene, at temperatures of 20-100 °C, preferably at 50-70 °C.
  • the reaction products III are isolated per crystallization or chromatography.
  • the compounds according to the invention are prepared by the methods of synthesis
  • the process for the synthesis of compounds of formula I, II or III comprises the following steps for the synthesis of compounds of formula E.
  • a compound of formula is obtained by deprotection of a compound of formula wherein A is absent or is a 6-membered nitrogen containing heteroaryl optionally substituted with a -C 1-3 alkyl group.
  • deprotection is obtained in basic conditions.
  • the deprotection of alkyne H to give E is carried out in the presence of a base such as NaH, KOH or K 3 PO 4 or combinations thereof in an organic solvent such as toluene, xylene, 2-methyltetrahydrofuran or tetrahydrofuran at 40 °C to 100 °C. More preferably the reaction is carried out in toluene at 55 °C.
  • the product isolation is carried out as described below or used directly in solution in the next step.
  • 6-ethynyl-derivatives E may be synthesized in accordance with the processes shown in the synthesis Scheme III.
  • the 6-ethynyl-quinoline E1 is obtained by a two-step procedure consisting of an Sonogashira cross coupling with ethynyltrimethylsilane, followed by desilylation.
  • Alkynes of the type H are obtained by the two-step procedure shown in the synthesis Scheme III.
  • a Sonogashira cross coupling with 2-methyl-3-butyn-2-ol leads to H.
  • the sulfonic acid ester G is preferably prepared by reaction of the corresponding phenol F with toluenesulfonic acid chloride or benzensulfonic acid chloride in the presence of a base, preferably a tertiary amine base, preferably triethylamine and diisopropylethylamine.
  • the reaction is preferably carried out in an aprotic solvent such as dichloromethane, DMF, THF, acetonitrile or acetone at a temperature of 20-100 °C. More preferably the reaction is carried out in acetone at a temperature of 50-60 °C.
  • the product G can be isolated by crystallization or chromatography.
  • the reaction of the sulfonic acid ester with 2-methyl-3-butyn-2-ol is carried out in the presence of a palladium source, a ligand and a base.
  • a palladium source is used preferably a stable palladium salt such as palladium acetate.
  • ligand is preferably used a phosphine ligand such as 2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl ("RuPhos").
  • a carbonate base such as potassium carbonate is preferably used as the base.
  • the reaction can be carried out in alcohols, acetonitrile, ethers, toluene or water or mixtures of these at 40 °C to 100 °C. More preferably the reaction is carried out in 2-propanol/water mixtures at 75 °C to 85 °C. Subsequently, the solvent is replaced by a nonpolar solvent, preferably toluene, and the inorganic compounds are removed by aqueous washes.
  • the alkynes H can be isolated by crystallization or directly used in solution in the subsequent reaction step after an extractive work up and concentration of the organic extracts.
  • the deprotection reaction to give alkynes E occurs by treatment of alkynes H with a base.
  • a base such as an alkali hydroxide, carbonate or phosphate is employed and more preferably a mixture of potassium hydroxide and potassium phosphate is utilized.
  • the reaction is carried out in aprotic solvents such as toluene, THF, or acetonitrile, preferably toluene at temperatures of 25-120 °C, preferably 90-110 °C.
  • aprotic solvents such as toluene, THF, or acetonitrile, preferably toluene at temperatures of 25-120 °C, preferably 90-110 °C.
  • inorganic compounds are removed by filtration or aqueous work up and the organic phase is then used directly in the next reaction step.
  • alkynes of the type H may be prepared from (heterocyclic) bromides of the type D as shown in the synthesis Scheme II.
  • reaction of bromides D with 2-methyl-3-butyn-2-ol is carried out in the presence of a palladium source, a ligand, a copper(I) salt and a base.
  • a palladium source is used preferably a stable palladium salt such as bis(triphenylphosphine)palladium dichloride.
  • Preferred ligand is a phosphine ligand such as triphenylphosphine.
  • copper(I) salt is preferably used copper iodide and the preferred base is an amine such as triethylamine, diisopropylamine, diisopropylethylamine.
  • the reaction can be carried out in alcohols, acetonitrile, ethers, toluene or water or mixtures of these at 40 °C to 100 °C. More preferably the reaction is carried out in 2-methyltetrahydrofuran at 80 °C.
  • the product isolation is carried out as described above or crystallized from an appropriate solvent such as iPrOAc.
  • halogenoimidazopyridines K are obtained from pyridinium salts of the type C by a cyclization to imidazo[1,2- a ]pyridines J followed by a halogenation step as shown in synthesis Scheme IV.
  • the cyclization may be mediated by an appropriate base such as a strong inorganic base, preferably sodium hydroxide, and is carried out in a protic or aprotic solvent such as acetonitrile, methanol and THF, preferably in methanol.
  • a protic or aprotic solvent such as acetonitrile, methanol and THF, preferably in methanol.
  • the reaction is maintained at a temperature of about 5 °C to 60 °C and preferably at 15 °C to 35 °C.
  • the halogenation agent e.g. N -iodosuccinimide
  • the reaction products K are isolated per crystallization or chromatography.
  • 6-Bromo-1-chloro-isoquinoline (60.0 g, 0.24 mol) is combined with Me-THF (270 mL) and tetramethylethylendiamine (18.7 mL, 0.12 mol) is added, rinsing with Me-THF (5 mL).
  • Iron(III)acetylacetonate (437 mg, 1.24 mmol) is added, rinsing with Me-THF (5 mL).
  • the resulting mixture is cooled to 0 °C and methyl magnesium chloride, 3.0 M in THF (86.6 mL, 0.26 mol) is added at 0-2 °C in 1 h, rinsing with Me-THF (20 mL).
  • E2 and E3 can be prepared under analogous conditions (analogous conditions include potential deviations from the disclosed conditions in terms of, e.g., solvent, reaction conditions or purification which the skilled artisan is familiar with and takes into account):
  • analogous conditions include potential deviations from the disclosed conditions in terms of, e.g., solvent, reaction conditions or purification which the skilled artisan is familiar with and takes into account):
  • E1 MS (ESI + ) m/z 154 [M+H] +
  • E2 MS (ESI + ) m/z 168 [M+H] +
  • E3 MS (ESI + ) m/z 168 [M+H] +
  • the 1-methyl-isoquinolin-6-ol may be synthesized following literature procedures ( Journal of Organic Chemistry USSR, English Translation, 1992, 28, 642-646 ).
  • alkyne E3 may be isolated before performing the Sonogashira reaction.
  • MS (ESI + ) m/z 168 [M+H] + .
  • the intermediates III can be further functionalized by performing cross coupling reactions at the 5-position bearing the halogen atom with the appropriate imidazo[1,2- a ]pyridine as shown in the synthesis Scheme V.
  • 2-Amino-1-(prop-2-yn-1-yl)pyridin-1-ium bromide C1 (150.0 g, 0.66 mol) is suspended in methanol (600 mL) and 4 N sodium hydroxide aq. solution (530.0 mL, 2.12 mol) is added in 30 min at 15-35 °C. After stirring for 2 h at 20 °C, N -iodosuccinimide (175.0 g, 0.78 mol) is added in portions to the resulting solution of 2-methylimidazo[1,2- a ]pyridine J1 at 21-24 °C.
  • the 3-halogeno-imidazo[1,2- a ]pyridines K can be metallated and subsequently cross coupled with III in the presence of a palladium source, a ligand and optionally of other additives.
  • the halogen atom is preferably iodine.
  • the metallation step can be carried out with an appropriate metallating agent such as isopropylmagnesium chloride or isopropylmagnesium chloride lithium chloride complex solutions followed by a treatment with a transmetallating agent such as ZnBr 2 or ZnCl 2 .
  • the metallation/transmetallation sequence reaction is preferably carried out in ethers (e.g. Me-THF or THF) or in polar aprotic solvents ( e.g .
  • the solution of the metallated imidazo[1,2- a ]pyridine is then combined with a solution of III and cross coupled in the presence of a palladium catalyst and a ligand.
  • palladium source preferably a stable palladium salt or complex such as bis(dibenzylideneacetone)palladium, tri(dibenzylideneacetone)dipalladium, Pd(OAc) 2 , Pd(OPiv) 2 , tetrakis(triphenylphosphine)palladium, bis(triphenylphosphinepalladium)-dichloride, Preferably bis(dibenzylideneacetone)palladium.
  • a stable palladium salt or complex such as bis(dibenzylideneacetone)palladium, tri(dibenzylideneacetone)dipalladium, Pd(OAc) 2 , Pd(OPiv) 2 , tetrakis(triphenylphosphine)palladium, bis(triphenylphosphinepalladium)-dichloride, Preferably bis(dibenzylideneacetone)palladium.
  • a phosphine ligand such as triphenylphosphine, t BuXPhos, BrettPhos, RuPhos, SPhos, di(1-adamantyl)- n -butylphosphine.
  • Preferred ligand is RuPhos.
  • the cross coupling step is carried out at a temperature of 20-80 °C and preferably at 40-65 °C.
  • the reaction products II can be thus isolated or the N , N -dimethylformamidine moiety can be cleaved during the acidic aqueous work up to produce the aminopyridines M which are isolated per crystallization or chromatography.
  • N , N- dimethylformamidine protecting group in compounds II can be removed using basic conditions which are even more compatible with the presence of an alkyne moiety, such as sodium hydroxide, ammonium hydroxide or ethylenediamine ( J. Org. Chem., 2008, 73 (22), 8954-8959 ).
  • the imidazo[1,2- a ]pyridines J can be cross coupled with III in the presence of a palladium source, a ligand, a base and optionally of other additives.
  • a palladium source is used preferably a stable palladium salt or complex such as Pd(OAc) 2 , Pd(OPiv) 2 , PdCl 2 [( t -Bu) 2 PCl] 2 , tetrakis(triphenylphosphine)palladium, bis(triphenylphosphinepalladium) dichloride.
  • a phosphine ligand such as triphenylphosphine, (4-CF 3 -C 6 H 4 ) 3 P, (4-F-C 6 H 4 ) 3 P, (4-MeOC 6 H 4 ) 3 P, (2-MeC 6 H 4 ) 3 P, cHex 3 P, t BuXPhos, BrettPhos, RuPhos, (PhO) 3 P, di(1-adamantyl)- n- butylphosphine.
  • Preferred ligand are triphenylphosphine or di(1-adamantyl)- n- butylphosphine.
  • an appropriate base such as an inorganic base such as Cs 2 CO 3 , K 2 CO 3 or (NH 4 ) 2 CO 3 , and preferably Cs 2 CO 3 .
  • pivalic acid isobutyric acid or m NO 2 C 6 H 4 COOH may be used.
  • the reaction is carried out in a polar solvent such as DMSO, DMF, NMP, nBuOH, dioxane, DMPU and preferably DMSO at a temperature of 50-130 °C and preferably at 90 °C to 120 °C.
  • the reaction products II are isolated per crystallization or chromatography.
  • the resulting solution of the zinc reagent is added over 30 min to a mixture of compound III-3 (2.0 g, 6.09 mmol), bis(dibenzylideneacetone)palladium(0) (105 mg, 0.18 mmol) and RuPhos (170 mg, 0.36 mmol) in dry THF (8 mL) at 45-50°C, rinsing with dry THF (4 mL), and the reaction mixture is stirred overnight at this temperature.
  • the reaction mixture is cooled to 20 °C and treated with 4 N of aqueous hydrochloric acid (10 mL) and water (14 mL).
  • the organic phase is separated and the aqueous phase basified with aqueous ammonia and extracted with DCM.
  • the formamidine protecting group present in compounds II can be removed under aqueous acidic or basic conditions.
  • Compounds M can be further functionalized at the 2-amino moiety, e.g . by acylation with an appropriate protected aminoacid, to produce SMAC mimetics compounds as those reported in the patent US 2013/0225567 using the general method reported on page 23.
  • amide formation starting from the appropriate protected amino acid can also be used.
  • a combination of T3P (Propylphosphonic Anhydride) in an organic solvent such as dichloromethane, pyridine, tetrahydrofurane, acetonitrile, ethyl acetate or mixture thereof at a temperature of -30 - +30 °C, preferably at -20/-15 °C.
  • Boc-protective groups can be performed as described in WO 2013/127729 and WO 2016/023858 .
  • N1, N2 and N4 to N6 can be prepared under analogous conditions by amide coupling of precursors M (analogous conditions include potential deviations from the disclosed conditions in terms of, e.g., solvent, reaction conditions or purification which the skilled artisan is familiar with and takes into account).
  • analogous conditions include potential deviations from the disclosed conditions in terms of, e.g., solvent, reaction conditions or purification which the skilled artisan is familiar with and takes into account).
  • N1 MS (ESI + ) m/z 668 [M+H] +
  • N2 MS (ESI + ) m/z 682 [M+H] +
  • N4 MS (ESI + ) m/z 617 [M+H] +
  • N5 MS (ESI + ) m/z 682 [M+H] +
  • N6 MS (ESI + ) m/z 561 [M+H] +

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP17726859.6A 2016-05-19 2017-05-17 Process for the manufacture of 6-alkynyl-pyridine derivatives Active EP3458441B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16170489 2016-05-19
PCT/EP2017/061885 WO2017198734A1 (en) 2016-05-19 2017-05-17 Process for the manufacture of 6-alkynyl-pyridine derivatives

Publications (2)

Publication Number Publication Date
EP3458441A1 EP3458441A1 (en) 2019-03-27
EP3458441B1 true EP3458441B1 (en) 2021-01-20

Family

ID=56024203

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17726859.6A Active EP3458441B1 (en) 2016-05-19 2017-05-17 Process for the manufacture of 6-alkynyl-pyridine derivatives

Country Status (14)

Country Link
US (1) US11053237B2 (ja)
EP (1) EP3458441B1 (ja)
JP (1) JP6940524B2 (ja)
KR (1) KR102392581B1 (ja)
CN (1) CN109153645B (ja)
AU (1) AU2017266291B2 (ja)
BR (1) BR112018071289A2 (ja)
CA (1) CA3023520A1 (ja)
CL (1) CL2018003159A1 (ja)
EA (1) EA038950B1 (ja)
IL (1) IL262889B (ja)
MX (1) MX2018014103A (ja)
PH (1) PH12018502377A1 (ja)
WO (1) WO2017198734A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108084090B (zh) * 2017-12-20 2020-03-17 北京六合宁远科技有限公司 一种药物中间体含氮杂环的溴代化合物的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060234360A1 (en) 2005-04-13 2006-10-19 Paola Branduardi Ascorbic acid production from D-glucose in yeast
MX2007015419A (es) 2005-06-08 2008-02-21 Novartis Ag Compuestos organicos.
WO2007101347A1 (en) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
CN101595093A (zh) 2006-12-07 2009-12-02 诺瓦提斯公司 有机化合物
US8859541B2 (en) * 2012-02-27 2014-10-14 Boehringer Ingelheim International Gmbh 6-alkynylpyridines
US9278978B2 (en) 2013-08-23 2016-03-08 Boehringer Ingelheim International Gmbh 6-Alkynyl Pyridine
US9249151B2 (en) 2013-08-23 2016-02-02 Boehringer Ingelheim International Gmbh Bis-amido pyridines
AR101479A1 (es) * 2014-08-11 2016-12-21 Boehringer Ingelheim Int Derivados de 6-alquinil-piridina

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
US20190308967A1 (en) 2019-10-10
MX2018014103A (es) 2019-04-29
CA3023520A1 (en) 2017-11-23
IL262889B (en) 2021-01-31
EA038950B1 (ru) 2021-11-12
IL262889A (en) 2018-12-31
AU2017266291A1 (en) 2018-10-25
KR102392581B1 (ko) 2022-04-28
EP3458441A1 (en) 2019-03-27
PH12018502377B1 (en) 2019-04-08
AU2017266291B2 (en) 2021-07-01
US11053237B2 (en) 2021-07-06
KR20190008261A (ko) 2019-01-23
EA201892615A1 (ru) 2019-06-28
PH12018502377A1 (en) 2019-04-08
BR112018071289A2 (pt) 2019-02-05
CN109153645A (zh) 2019-01-04
JP6940524B2 (ja) 2021-09-29
CL2018003159A1 (es) 2019-02-15
JP2019516704A (ja) 2019-06-20
CN109153645B (zh) 2022-06-21
WO2017198734A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
AU2002251546B2 (en) Pyrazolo[1,5-A]pyridines and medicines containing the same
JP5612573B2 (ja) 新規化学化合物
US7902219B2 (en) 2-benzoylimidazopyridine derivatives, preparation and therapeutic use thereof
CA2537829A1 (en) Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands
KR20180006334A (ko) 신규한 4-아미노피라졸로[3,4-d]피리미디닐아자바이사이클로 유도체 및 이를 포함하는 약학 조성물
JP2009531274A (ja) キナーゼ阻害性ピロロピリジン化合物
JP2011528026A6 (ja) 新規化学化合物
AU2009253231A1 (en) Polysubstituted derivatives of 2-aryl-6-phenyl-imidazo[1,2-a] pyridines, and preparation and therapeutic use thereof
CA2944697C (en) Manufacturing process for triazine, pyrimidine and pyridine derivatives
EP2727920A1 (en) 1,5-naphthyridine derivative or salt thereof
CN111440164A (zh) 6-炔基-吡啶衍生物
KR20100109941A (ko) 이미다조［１,２-ａ］피리딘-２-카르복스아미드 유도체, 그의 제법 및 치료제에서 그의 용도
EP3458441B1 (en) Process for the manufacture of 6-alkynyl-pyridine derivatives
KR20230058466A (ko) 신규한 rho-연관 단백질 인산화효소 억제제의 제조 방법 및 제조 방법 중의 중간체
KR20200109314A (ko) 아미노-피리미딘 및 이의 중간체의 제조 공정
CN101910172A (zh) N-杂环咪唑并[1，2-a]吡啶-2-甲酰胺衍生物、其制备方法及其治疗应用
KR101600635B1 (ko) ６-헤테로시클릭-이미다조［１,２-ａ］피리딘-２-카르복스아미드의 유도체, 그의 제법 및 그의 치료학적 용도
KR20100099245A (ko) Ｎ-페닐-이미다조［１,２-ａ］피리딘-2-카르복스아미드의 유도체, 그의 제법 및 그의 치료학적 용도
AU2008352729B8 (en) 2-benzoylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof
KR20100103660A (ko) Ｎ-헤테로시클릭-６-헤테로시클릭-이미다조［１,２-ａ］피리딘-２-카르복스아미드의 유도체, 그의 제법 및 그의 치료학적 용도
JP2023533850A (ja) Ａｌｋ５阻害剤としてのピリドオキサジンアミノ誘導体
EP3026054B1 (en) Hetero-condensed ring compound
JP2011508763A (ja) ２−ヘテロアロイルイミダゾ［１，２−ａ］ピリジン誘導体、この調製および治療用途

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20200311

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20200812

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602017031657

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1356277

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20210120

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1356277

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210420

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210520

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210120

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210120

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210421

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210120

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210420

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210120

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210120

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210120

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210120

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210520

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602017031657

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210120

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210120

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210120

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210120

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210120

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210120

VS25 Lapsed in a validation state [announced via postgrant information from nat. office to epo]

Ref country code: MD

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210120

26N No opposition filed

Effective date: 20211021

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210517

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210531

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210120

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210120

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210531

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210120

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20210531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210120

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210517

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210520

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210531

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210120

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20170517

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210120

VS25 Lapsed in a validation state [announced via postgrant information from nat. office to epo]

Ref country code: MA

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210120

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240521

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240521

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240528

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210120